Welcome to AngioPredict
ANGIOPREDICT - an FP7-funded project enabling personalised medicine for patients with metastatic colorectal cancer.
About AngioPredict
In ANGIOPREDICT, academic cancer biologists and industry-based biotechnology researchers will work together with clinicians to identify biomarkers to predict whether individual metastatic colorectal cancer patients will respond positively to AvastinĀ® combination therapy. Diagnostic tests using these biomarkers will also be developed to provide clinicians with the means to predict patient treatment responses in the future.